PMID: 7204716Jan 1, 1980Paper

Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients

Journal of Dialysis
M H BiermanJ D Egan

Abstract

Vancomycin therapy during 7 episodes of serious staphylococcal infections in chronic hemodialysis patients was monitored by a sensitive bioassay technique. One gm of vancomycin was given during dialysis at a mean dosage interval of 7 days for a mean duration of 48 days. Serum peak and trough vancomycin levels were monitored during therapy. Accumulation of vancomycin occurred in 1 patient on prolonged therapy; progressive rising through levels required a reduction in vancomycin dosage. Pre and post-dialysis vancomycin levels in one patient were unchanged. Vancomycin was effective in eradication of all staphylococcal infections and bacteremias. Three A-V shunt infections required surgical revision; 2 A-V fistula infections were salvaged with vancomycin therapy alone. We conclude that 1 gm vancomycin every 7 days is an effective regimen for serious staphylococcal infections in chronic hemodialysis patients. Monitoring of vancomycin levels insures maintenance of adequate levels and prevents toxic accumulation.

References

Oct 27, 1978·JAMA : the Journal of the American Medical Association·R J FavilleP G Quie
Jun 1, 1978·Annals of Internal Medicine·F V Cook, W E Farrar
Jan 1, 1978·Antimicrobial Agents and Chemotherapy·C A Walker, B Kopp
Apr 1, 1975·Acta Medica Scandinavica·H E NielsenP E Skov
May 12, 1966·The New England Journal of Medicine·D D Lindholm, J S Murray

Citations

Jan 1, 1994·International Urology and Nephrology·J AlwakeelH Abu-aisha
Jan 1, 1994·Kidney International·T A PollardB J Maroni
Aug 10, 2006·Néphrologie & thérapeutique·Alain Meyrier
Sep 29, 2011·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Kostas I SombolosChristina I Fytili

Related Concepts

Dose-Response Relationship, Drug
Hemodialysis
Kidney Failure, Chronic
Staphylococcal Infections
AB-Vancomycin

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.